Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Théa Open Innovation
TORONTO, ON / ACCESSWIRE / December 15, 2020 / Ripple Therapeutics Corporation ("Ripple" or "the Company"), a clinical stage, ophthalmology-focused developer of novel therapeutics, announced today the signing of an exclusive Licensing Agreement for the rights to their lead product, IBE-814, for North America and Europe with Théa Open Innovation ("TOI") a wholly owned subsidiary of Laboratoires Théa, the leading independent ophthalmology pharmaceutical company in Europe. In addition to the Licensing Agreement, Ripple announced that TOI is leading their Series A Financing.
Ripple's Epidel
® technology platform is founded on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. The proprietary prodrugs have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants and micro/nanoparticles) or as coatings on medical devices. The implants and coatings undergo surface erosion to give zero order drug release kinetics and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest.